|
| Press Releases |
|
 |
|
| Thursday, June 12, 2025 |
|
|
JBM Healthcare Delivers Strong FY2025 Annual Results, Net Profit Surged 51.2% to HK$197.3 Million |
| JBM (Healthcare) Limited ('JBM Healthcare' or the 'Company'; Stock Code: 2161, together with its subsidiaries, the 'Group'), a leading branded healthcare products marketer and distributor in Hong Kong, today announced the annual results of the Group for the year ended 31 March 2025 ('FY2025' or the 'Reporting Period'). more info >> |
|
|
健倍苗苗二零二五財年全年業績表現亮眼 純利飆升51.2%至1.97億港元 |
| 健倍苗苗（保健）有限公司（「健倍苗苗」或「公司」；股份代號：2161，連同其附屬公司統稱「集團」）為香港品牌保健品的領先營銷商及分銷商，集團今天公佈截至二零二五年三月三十一日止年度（「二零二五財年」或「報告期」）的全年業績。 more info >> |
|
|
健倍苗苗二零二五财年全年业绩表现亮眼 纯利飙升51.2%至1.97亿港元 |
| 健倍苗苗（保健）有限公司（「健倍苗苗」或「公司」；股份代号：2161，连同其附属公司统称「集团」）为香港品牌保健品的领先营销商及分销商，集团今天公布截至二零二五年三月三十一日止年度（「二零二五财年」或「报告期」）的全年业绩。 more info >> |
|
| Thursday, April 3, 2025 |
|
|
JBM Healthcare Completes Acquisition of 90% Interest in Tin Hee Tong |
| JBM (Healthcare) Limited ("JBM Healthcare"; Stock Code: 2161, together with its subsidiaries, the "Group"), a leading branded healthcare products marketer and distributor in Hong Kong, announced today that it has acquired a 90% stake in Tin Hee Tong Medicine Factory, Limited ("Tin Hee Tong",), at a total consideration of HK$171.0 million. more info >> |
|
|
健倍苗苗完成收購天喜堂90%股權 |
| 香港領先的品牌保健品營銷商及分銷商健倍苗苗（保健）有限公司 （「健倍苗苗」；股份代號：2161，連同其附屬公司統稱「集團」）今天公布已完成收購天喜堂藥廠有限公司（「天喜堂」）90%股權，總代價為171.0百萬港元。天喜堂現正式成為健倍苗苗的非全資附屬公司。 more info >> |
|
|
健倍苗苗完成收购天喜堂90%股权 |
| 香港领先的品牌保健品营销商及分销商健倍苗苗（保健）有限公司 （「健倍苗苗」；股份代号：2161，连同其附属公司统称「集团」）今天公布已完成收购天喜堂药厂有限公司（「天喜堂」）90%股权，总代价为171.0百万港元。天喜堂现正式成为健倍苗苗的非全资附属公司。 more info >> |
|
| Wednesday, November 27, 2024 |
|
|
林峯飛鷹活絡油廣告成熱話 母企健倍苗苗深諳品牌營銷致勝之道 |
| 最近，尖沙咀天星小輪附近一個大型戶外廣告引發網民熱議，廣告主角林峯「金雞獨立」並高舉雙手，儼如飛鷹展翅，神似大阪地標「固力果跑跑人」，極為吸睛。 more info >> |
|
| Tuesday, November 19, 2024 |
|
|
JBM Healthcare Announces FY2025 Interim Results |
| more info >> |
|
|
健倍苗苗公佈二零二五財年中期業績 純利飆升53.4%至95.9百萬港元 |
| more info >> |
|
|
健倍苗苗公布二零二五财年中期业绩 纯利飙升53.4%至95.9百万港元 |
| more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Naoris Protocol Announces Upcoming TGE for $NAORIS
Jul 29, 2025 23:59: JST
|
|
|
Naoris Protocol Announces Upcoming TGE for $NAORIS
Jul 29, 2025 23:59 HKT/SGT
|
|
|
Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence
Jul 29, 2025 23:39 HKT/SGT
|
|
|
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Jul 29, 2025 23:13 HKT/SGT
|
|
|
GTJAI Achieved 'Carbon Neutrality' at Operational Level for the Third Consecutive Year
Jul 29, 2025 23:06 HKT/SGT
|
|
|
Mitsubishi Heavy Industries Concludes Agreement with Modius to Provide DCIM Solutions for Data Centers Worldwide
Jul 29, 2025 20:00 JST
|
|
|
Wintermar Offshore (WINS:JK) Reports 1H2025 Results
Jul 29, 2025 18:56 HKT/SGT
|
|
|
Set at the Osaka-Kansai Expo venue! Detailed program announced for the "OSAKA JAPAN SDGs Forum"
Jul 29, 2025 14:30 JST
|
|
|
Unitree Races Toward IPO as Robot Applications Accelerate: Shoucheng Holdings Unlocks Dual-Engine Gains
Jul 29, 2025 11:30 HKT/SGT
|
|
|
宇樹衝刺IPO、機械人應用加速落地：首程控股雙輪驅動兌現紅利
Jul 29, 2025 11:30 HKT/SGT
|
|
|
宇树冲刺IPO、机器人应用加速落地：首程控股双轮驱动兑现红利
Jul 29, 2025 11:30 HKT/SGT
|
|
|
國泰君安國際連續第三年實現營運層面「碳中和」
Jul 29, 2025 11:19 HKT/SGT
|
|
|
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
Jul 29, 2025 9:01 JST
|
|
|
GEN 與 Sulfateq BV 公佈治療阿茲海默症及其他神經退化性疾病的候選藥物 SUL-238 的第一階段臨床試驗正面結果
Jul 29, 2025 08:00 HKT/SGT
|
|
|
GEN 与 Sulfateq BV 公布治疗阿尔茨海默病及其他神经退行性疾病的候选药物 SUL-238 的第一阶段临床试验积极结果
Jul 29, 2025 08:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
